{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T05:11:22Z","timestamp":1794028282650,"version":"4.8.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T00:00:00Z","timestamp":1748476800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T00:00:00Z","timestamp":1748476800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100017559","name":"Recordati Rare Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017559","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s12325-025-03229-0","type":"journal-article","created":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T03:35:49Z","timestamp":1748489749000},"page":"3472-3485","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Matching-Adjusted Indirect Comparison of Osilodrostat Versus Metyrapone for the Treatment of Cushing\u2019s Syndrome"],"prefix":"10.1007","volume":"42","author":[{"given":"Conor","family":"Hickey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice","family":"Gueron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-6984-1425","authenticated-orcid":false,"given":"Emma","family":"Tyas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grzegorz","family":"Binowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9632-1348","authenticated-orcid":false,"given":"Rosario","family":"Pivonello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,29]]},"reference":[{"issue":"2","key":"3229_CR1","doi-asserted-by":"publisher","first-page":"237","DOI":"10.4183\/aeb.2019.237","volume":"15","author":"O Chabre","year":"2019","unstructured":"Chabre O, Cristante J. Treatment of cushing\u2019s syndrome: What place for medical treatment? Acta Endocrinologica (Bucharest). 2019;15(2):237\u201343.","journal-title":"Acta Endocrinologica (Bucharest)"},{"issue":"9996","key":"3229_CR2","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/S0140-6736(14)61375-1","volume":"386","author":"A Lacroix","year":"2015","unstructured":"Lacroix A, Feelders R, Stratakis C, Nieman L. Cushing\u2019s syndrome. The lancet. 2015;386(9996):913\u201327.","journal-title":"The lancet"},{"issue":"5","key":"3229_CR3","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1530\/EJE-19-0464","volume":"181","author":"E Valassi","year":"2019","unstructured":"Valassi E, Tabarin A, Brue T, Feelders R, Reincke M, Netea-Maier R, et al. High mortality within 90 days of diagnosis in patients with Cushing\u2019s syndrome: results from the ERCUSYN registry. Eur J Endocrinol. 2019;181(5):461\u201372.","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"3229_CR4","doi-asserted-by":"publisher","first-page":"139","DOI":"10.3803\/EnM.2018.33.2.139","volume":"33","author":"L Nieman","year":"2018","unstructured":"Nieman L. Recent updates on the diagnosis and management of Cushing\u2019s syndrome. Endocrinol Metab. 2018;33(2):139\u201346.","journal-title":"Endocrinol Metab"},{"issue":"4","key":"3229_CR5","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1210\/er.2013-1048","volume":"36","author":"R Pivonello","year":"2015","unstructured":"Pivonello R, De Leo M, Cozzolino A, Colao A. The treatment of Cushing\u2019s disease. Endocr Rev. 2015;36(4):385\u2013486.","journal-title":"Endocr Rev"},{"issue":"5","key":"3229_CR6","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1210\/jc.2008-0125","volume":"93","author":"L Nieman","year":"2008","unstructured":"Nieman L, Biller B, Findling J, Newell-Price J, Savage M, Stewart P, et al. The diagnosis of Cushing\u2019s syndrome: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2008;93(5):1526\u201340.","journal-title":"J Clin Endocrinol Metab"},{"key":"3229_CR7","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s42000-019-00163-z","volume":"19","author":"I Lase","year":"2020","unstructured":"Lase I, Strele I, Gr\u00f6nberg M, Kozlovacki G, Welin S, Janson E. Multiple hormone secretion may indicate worse prognosis in patients with ectopic Cushing\u2019s syndrome. Hormones. 2020;19:351\u201360.","journal-title":"Hormones"},{"issue":"7","key":"3229_CR8","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/S2213-8587(16)00086-3","volume":"4","author":"R Pivonello","year":"2016","unstructured":"Pivonello R, Isidori A, De Martino M, Newell-Price J, Biller B, Colao A. Complications of Cushing\u2019s syndrome: state of the art. Lancet Diabetes Endocrinol. 2016;4(7):611\u201329.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"3229_CR9","first-page":"281","volume":"7","author":"ST Sharma","year":"2015","unstructured":"Sharma ST, Nieman LK, Feelders RA. Cushing\u2019s syndrome: epidemiology and developments in disease management. Clin Epidemiol. 2015;7:281\u201393.","journal-title":"Clin Epidemiol"},{"issue":"5","key":"3229_CR10","first-page":"1119","volume":"62","author":"L Kirk Jr","year":"2000","unstructured":"Kirk L Jr, Hash R, Katner H, Jones T. Cushing\u2019s disease: clinical manifestations and diagnostic evaluation. Am Fam Physician. 2000;62(5):1119\u201327.","journal-title":"Am Fam Physician"},{"issue":"1","key":"3229_CR11","first-page":"117","volume":"86","author":"J Lindholm","year":"2001","unstructured":"Lindholm J, Juul S, J\u00f8rgensen J, Astrup J, Bjerre P, Feldt-Rasmussen U, et al. Incidence and late prognosis of Cushing\u2019s syndrome: a population-based study. J Clin Endocrinol Metab. 2001;86(1):117\u201323.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"3229_CR12","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1111\/j.1365-2265.1994.tb02486.x","volume":"40","author":"J Etxabe","year":"1994","unstructured":"Etxabe J, Vazquez J. Morbidity and mortality in Cushing\u2019s disease: an epidemiological approach. Clin Endocrinol. 1994;40(4):479\u201384.","journal-title":"Clin Endocrinol"},{"key":"3229_CR13","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s11102-014-0569-6","volume":"18","author":"M Broder","year":"2015","unstructured":"Broder M, Neary M, Chang E, Cherepanov D, Ludlam W. Incidence of Cushing\u2019s syndrome and Cushing\u2019s disease in commercially-insured patients less than 65 years old in the United States. Pituitary. 2015;18:283\u20139.","journal-title":"Pituitary"},{"issue":"2","key":"3229_CR14","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1001\/jama.2023.11305","volume":"330","author":"M Reincke","year":"2023","unstructured":"Reincke M, Fleseriu M. Cushing syndrome: a review. JAMA. 2023;330(2):170\u201381.","journal-title":"JAMA"},{"issue":"5","key":"3229_CR15","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1007\/s11102-022-01262-8","volume":"25","author":"R Pivonello","year":"2022","unstructured":"Pivonello R, Simeoli C, Di Paola N, Colao A. Cushing\u2019s disease: adrenal steroidogenesis inhibitors. Pituitary. 2022;25(5):726\u201332.","journal-title":"Pituitary"},{"issue":"9","key":"3229_CR16","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/S2213-8587(20)30240-0","volume":"8","author":"R Pivonello","year":"2020","unstructured":"Pivonello R, Fleseriu M, Newell-Price J, Bertagna X, Findling J, Shimatsu A, et al. Efficacy and safety of osilodrostat in patients with Cushing\u2019s disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase. Lancet Diabetes Endocrinol. 2020;8(9):748\u201361.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"7","key":"3229_CR17","doi-asserted-by":"publisher","first-page":"e2882","DOI":"10.1210\/clinem\/dgac178","volume":"107","author":"M Gadelha","year":"2022","unstructured":"Gadelha M, Bex M, Feelders R, Heaney A, Auchus R, Gilis-Januszewska A, et al. Randomized trial of osilodrostat for the treatment of Cushing disease. J Clin Endocrinol Metab. 2022;107(7):e2882\u201395.","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"3229_CR18","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1507\/endocrj.EJ19-0617","volume":"67","author":"T Tanaka","year":"2020","unstructured":"Tanaka T, Satoh F, Ujihara M, Midorikawa S, Kaneko T, Takeda T, et al. A multicenter, phase 2 study to evaluate the efficacy and safety of osilodrostat, a new 11\u03b2-hydroxylase inhibitor, in Japanese patients with endogenous Cushing\u2019s syndrome other than Cushing\u2019s disease. Endocr J. 2020;67(8):841\u201352.","journal-title":"Endocr J"},{"issue":"187","key":"3229_CR19","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1530\/EJE-22-0317","volume":"4","author":"M Fleseriu","year":"2022","unstructured":"Fleseriu M, Newell-Price J, Pivonello R, Shimatsu A, Auchus RJ, Scaroni C, et al. Long-term outcomes of osilodrostat in Cushing\u2019s disease: LINC 3 study extension. Eur J Endocrinol. 2022;4(187):531\u201341.","journal-title":"Eur J Endocrinol"},{"issue":"99","key":"3229_CR20","first-page":"1375","volume":"4","author":"X Bertagna","year":"2013","unstructured":"Bertagna X, Pivonello R, Fleseriu M, Zhang Y, Robinson P, Taylor A, et al. LCI699, a potent 11\u03b2-hydroxylase inhibitor, normalizes urinary cortisol in patients with Cushing\u2019s disease: results from a multicenter, proof-of-concept study. J Clin Endocrinol Metab. 2013;4(99):1375\u201383.","journal-title":"J Clin Endocrinol Metab"},{"issue":"19","key":"3229_CR21","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1007\/s11102-015-0692-z","volume":"2","author":"M Fleseriu","year":"2016","unstructured":"Fleseriu M, Pivonello R, Young J, Hamrahian AH, Molitch ME, Shimizu C, et al. Osilodrostat, a potent oral 11\u03b2-hydroxylase inhibitOR 22-week, prospective, Phase II study in Cushing\u2019s disease. Pituitary. 2016;2(19):138\u201348.","journal-title":"Pituitary"},{"issue":"25","key":"3229_CR22","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1007\/s11102-022-01280-6","volume":"6","author":"M Fleseriu","year":"2022","unstructured":"Fleseriu M, Biller BMK, Bertherat J, Young J, Hatipoglu B, Arnaldi G, et al. Long-term efficacy and safety of osilodrostat in Cushing\u2019s disease: final results from a Phase II study with an optional extension phase (LINC 2). Pituitary. 2022;6(25):959\u201370.","journal-title":"Pituitary"},{"key":"3229_CR23","unstructured":"Recordati Rare Diseases, Inc. Isturisa (osilodrostat) [package insert]. U.S. Food and Drug Administration website. [Online]. 2020. [cited 2024 August 23]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/212801s000lbl.pdf."},{"key":"3229_CR24","unstructured":"Recordati Rare Diseases UK Ltd. Isturisa 1 mg film coated tablets summary of product characteristics. Electronic Medicines Compendium. [Online]. 2024 [cited 2024 August 23]. Available from: https:\/\/www.medicines.org.uk\/emc\/product\/11587\/smpc."},{"key":"3229_CR25","unstructured":"HRA Pharma UK and Ireland Limited. Metyrapone HRA 250mg soft capsules summary of product characteristics. Electronic Medicines Compendium. [Online]. 2024. [cited 2024 August 23]. Available from: https:\/\/www.medicines.org.uk\/emc\/product\/13897\/smpc."},{"issue":"6","key":"3229_CR26","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/S0895-4356(97)00049-8","volume":"50","author":"H Bucher","year":"1997","unstructured":"Bucher H, Guyatt G, Griffith L, Walter S. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol. 1997;50(6):683\u201391.","journal-title":"J Clin Epidemiol"},{"issue":"5","key":"3229_CR27","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1177\/0272989X12458724","volume":"33","author":"S Dias","year":"2013","unstructured":"Dias S, Sutton A, Ades A, Welton N. Evidence synthesis for decision making 2: a generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials. Med Decis Making. 2013;33(5):607\u201317.","journal-title":"Med Decis Making"},{"issue":"6","key":"3229_CR28","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/j.jval.2012.05.004","volume":"15","author":"J Signorovitch","year":"2012","unstructured":"Signorovitch J, Sikirica V, Erder M, Xie J, Lu M, Hodgkins P, et al. Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research. Value Health. 2012;15(6):940\u20137.","journal-title":"Value Health"},{"issue":"2","key":"3229_CR29","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1177\/0272989X17725740","volume":"38","author":"D Phillippo","year":"2018","unstructured":"Phillippo D, Ades A, Dias S, Palmer S, Abrams K, Welton N. Methods for population-adjusted indirect comparisons in health technology appraisal. Med Decis Making. 2018;38(2):200\u201311.","journal-title":"Med Decis Making"},{"key":"3229_CR30","doi-asserted-by":"crossref","unstructured":"Gadelha M, Snyder PJ, Witek P, Bex M, Belaya Z, Turcu AF, et al. Long-term efficacy and safety of osilodrostat in patients with Cushing\u2019s disease: results from the LINC 4 study extension. Front Endocrinol. 2023; 14.","DOI":"10.3389\/fendo.2023.1236465"},{"key":"3229_CR31","doi-asserted-by":"crossref","unstructured":"Nieman L, Boscaro M, Scaroni C, Deutschbein T, Mezosi E, Driessens N, et al. Metyrapone treatment in endogenous Cushing\u2019s syndrome: results at week 12 from PROMPT, a prospective international multicenter, open-label, phase III\/IV study. J Endocr Soc. 2021; 5(Supplement_1): A515","DOI":"10.1210\/jendso\/bvab048.1053"},{"key":"3229_CR32","unstructured":"HRA PHARMA. Clinical trial results: prospective, single arm, open-label, multicenter, international study to assess the effects of metyrapone in patients with endogenous Cushing's syndrome during a 12-week treatment period followed by an extension period of 24 weeks. [Online]. 2022. [cited 2024 August 23]. Available from: https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2014-000162-22\/results."},{"key":"3229_CR33","unstructured":"Member State Coordination Group on HTA (HTA CG). Methodological guideline for quantitative evidence synthesis: direct and indirect comparisons. [Online]. 2024. [cited 2024 August 23]. Available from: https:\/\/health.ec.europa.eu\/document\/download\/4ec8288e-6d15-49c5-a490-d8ad7748578f_en?filename=hta_methodological-guideline_direct-indirect-comparisons_en.pdf."},{"key":"3229_CR34","unstructured":"Phillippo DM, Ades AE, Dias S, Palmer S, Abrams KR, Welton NJ. TSD 18: methods for population-adjusted indirect comparisons in submissions to NICE. [Online]. 2016. [cited 2024 September 19. Available from: https:\/\/www.sheffield.ac.uk\/nice-dsu\/tsds\/full-list."},{"key":"3229_CR35","doi-asserted-by":"publisher","first-page":"935","DOI":"10.2165\/11538370-000000000-00000","volume":"28","author":"J Signorovitch","year":"2010","unstructured":"Signorovitch J, Wu E, Yu A, Gerrits C, Kantor E, Bao Y, et al. Comparative effectiveness without head-to-head trials: a method for matching-adjusted indirect comparisons applied to psoriasis treatment with adalimumab or etanercept. Pharmacoeconomics. 2010;28:935\u201345.","journal-title":"Pharmacoeconomics"},{"key":"3229_CR36","unstructured":"R Core Team. R: a language and environment for Statistical Computing. [Online]; 2024. Available from: https:\/\/www.R-project.org\/."},{"issue":"4","key":"3229_CR37","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1002\/ajmg.a.38413","volume":"176","author":"L Kempf","year":"2018","unstructured":"Kempf L, Goldsmith J, Temple R. Challenges of developing and conducting clinical trials in rare disorders. Am J Med Genet A. 2018;176(4):773\u201383.","journal-title":"Am J Med Genet A"},{"key":"3229_CR38","doi-asserted-by":"crossref","unstructured":"Shimatsu A, Biller BM, Fleseriu M, Pivonello R, Lee EJ, Leelawattana R, et al. Osilodrostat treatment in patients with Cushing's disease of Asian or non-Asian origin: a pooled analysis of two Phase III randomized trials (LINC 3 and LINC 4) [Online ahead of print]. Endocr J. 2024.","DOI":"10.1507\/endocrj.EJ24-0153"},{"issue":"12","key":"3229_CR39","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/S2213-8587(21)00235-7","volume":"9","author":"M Fleseriu","year":"2021","unstructured":"Fleseriu M, Auchus R, Bancos I, Ben-Shlomo A, Bertherat J, Biermasz N, et al. Consensus on diagnosis and management of Cushing\u2019s disease: a guideline update. Lancet Diabetes Endocrinol. 2021;9(12):847\u201375.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"3229_CR40","doi-asserted-by":"crossref","unstructured":"Rajamohamed H. Comparison of the use of metyrapone and osilodrostat for cushing disease: a systemic review. J Adv Pharm Pract. 2024;(e-ISSN: 2582\u20134465): 12\u201324.","DOI":"10.46610\/JAPP.2024.v06i01.002"},{"key":"3229_CR41","doi-asserted-by":"crossref","unstructured":"Tyas E, Hickey C, Hemstock M, Binowski G, Rios C, Schmidt F. Comparative efficacy and safety of osilodrostat vs metyrapone for the treatment of Cushing\u2019s syndrome\u2014a matching-adjusted indirect treatment comparison (P132). In: 25th European Congress of Endocrinology. 2023; Istanbul","DOI":"10.1530\/endoabs.90.P132"},{"key":"3229_CR42","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.903545","volume":"13","author":"M Detomas","year":"2022","unstructured":"Detomas M, Altieri B, Deutschbein T, Fassnacht M, Dischinger U. Metyrapone versus osilodrostat in the short-term therapy of endogenous Cushing\u2019s syndrome: results from a single center cohort study. Front Endocrinol. 2022;13: 903545.","journal-title":"Front Endocrinol"},{"key":"3229_CR43","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1007\/s12020-016-0914-9","volume":"55","author":"V Guarnotta","year":"2017","unstructured":"Guarnotta V, Amato M, Pivonello R, Arnaldi G, Ciresi A, Trementino L, et al. The degree of urinary hypercortisolism is not correlated with the severity of cushing\u2019s syndrome. Endocrine. 2017;55:564\u201372.","journal-title":"Endocrine"},{"issue":"4","key":"3229_CR44","doi-asserted-by":"publisher","first-page":"R29","DOI":"10.1530\/EJE-19-0877","volume":"182","author":"J Young","year":"2020","unstructured":"Young J, Haissaguerre M, Viera-Pinto O, Chabre O, Baudin E, Tabarin A. Management of endocrine disease: cushing\u2019s syndrome due to ectopic ACTH secretion: an expert operational opinion. Eur J Endocrinol. 2020;182(4):R29-58.","journal-title":"Eur J Endocrinol"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03229-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03229-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03229-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T04:14:28Z","timestamp":1750479268000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03229-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,29]]},"references-count":44,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["3229"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03229-0","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,29]]},"assertion":[{"value":"20 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Rosario Pivonello has received research funding from Recordati AG, Corcept Therapeutics, Strongbridge Biopharma, Neurocrine Biosciences, Spruce Biosciences; and served as a consultant for Corcept Therapeutics, Recordati AG, Crinetics Pharmaceuticals, and H. Lundbeck A\/S. Beatrice Gueron and Fabian Schmidt are employees of Recordati Rare Diseases. Grzegorz Binowski served as a consultant to Recordati AG. Conor Hickey and Emma Tyas are employees of Lumanity, which received research funding from Recordati Rare Diseases for this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This research was based on previously conducted studies and does not contain any new studies performed by any of the authors with human participants or animals. The LINC-3 and LINC-4 clinical trials were conducted in accordance with the Declaration of Helsinki, and study protocols were approved by independent ethics committees\/institutional review boards. The PROMPT clinical trial was in compliance with the ethical principles derived from the Declaration of Helsinki and the International Conference on Harmonization Good Clinical Practice guidelines. All the local regulatory requirements pertinent to safety of trial subjects were also followed during the conduct of the trial.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}